|
Synonyms: 5F9vcMMAE [6] | MLN-0264 | MLN0264 | TAK-264 | TAK264
Compound class:
Antibody
Comment: Indusatumab vedotin was a clinical lead antibody-drug conjugate (ADC). It comprises an anti-guanylate cyclase 2C (GUCY2C) antibody linked to the synthetic antineoplastic toxin monomethyl auristatin E (MMAE, aka vedotin; PubChem CID 11542188).
Peptide sequence information for this antibody is available from its IMGT/mAb-DB record. A BLAST search of patented peptide sequences reveals that the heavy and light chain variable regions of indusatumab are identical to SEQ ID NO: 18 and SEQ ID NO: 20 respectively, from patent US8785600 B2 [6]. The patent also describes the toxin conjugation methodology. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
Classification  |
|
| Compound class | Antibody |
| International Nonproprietary Names |
|
| INN number | INN |
| 10033 | indusatumab vedotin |
| Synonyms |
|
| 5F9vcMMAE [6] | MLN-0264 | MLN0264 | TAK-264 | TAK264 | |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 532 |
| Other databases | |
| GtoPdb PubChem SID | 252827376 |
| Search PubMed clinical trials | indusatumab vedotin |
| Search PubMed titles | indusatumab vedotin |
| Search PubMed titles/abstracts | indusatumab vedotin |
